Biosimilar Medicine

The bill allows Tennessee's Medicaid program, TennCare, to encourage the use of cheaper biosimilar medications instead of brand-name drugs. It permits health insurance providers to require patients to try a biosimilar before covering the original branded medication. Additionally, a committee will consider biosimilars when recommending drugs for the state's preferred list.

Supporters of the bill argue that it will help reduce healthcare costs for both patients and the state by promoting the use of more affordable biosimilar drugs. They believe this measure will enhance access to necessary medications while maintaining quality care.

Critics of the bill contend that requiring patients to try biosimilars before accessing brand-name drugs may compromise individual patient care and lead to potential health risks. They express concerns that this policy could prioritize cost savings over the best medical options for patients.

The sponsor of HB1198, Sabi Kumar, has a documented personal financial interest in Pfizer, a major player in the pharmaceuticals and health products industry. The bill promotes the use of biosimilar drugs, which are directly related to the pharmaceutical sector. Given that Pfizer is a significant entity within this industry, any legislative action that affects the market dynamics of biosimilar drugs could potentially impact Pfizer's business operations and, consequently, the value of Kumar's investments. This presents a direct alignment between the sponsor's financial interests and the bill's impact, suggesting a potential conflict of interest. While Kumar's primary occupation as a surgeon and owner of a cosmetic surgery center does not directly relate to the bill, his investment in Pfizer does create a potential for personal financial gain, as the bill could influence the competitive landscape for biosimilar and branded drugs.

Unlike federal analysis based on campaign donations, state analysis examines legislators' personal financial interests — their jobs, businesses, and investments.

Items marked "AI-researched" are generated from public sources but have not been independently verified. Verified data is sourced from official legislature websites and disclosure filings.